Citing low demand, AstraZeneca announced May 8 it is withdrawing the vaccine from the market after supplying about 8 billion doses worldwide, according to a story by The Hill.
AstraZeneca’s vaccine, which was never authorized for use in the U.S., was much more common in poorer countries where a World Health Organization program named COVAX helped distribute it.
The shot was also distributed in Great Britain, where the corporation is headquartered. Great Britain is where more than 50 plaintiffs in a class-action lawsuit are accusing AstraZeneca’s vaccine of causing permanent brain injuries from a blood clot.
As part of that lawsuit, filed in 2023, AstraZeneca has now admitted in court documents the vaccine can, “in very rare cases,” cause blood clots, medically known as Thrombosis with Thrombocytopenia Syndrome, or TTS.
Vaccine critic Dr. Peter McCullough, of the McCullough Foundation, tells AFN the claim about pulling the vaccine due to market demand is not true.
“The arrangements were all pre-purchased contracts of vaccines,” he says.
Regarding the vaccine itself, Dr. McCullough says the problem is the spike protein, which in certain patients causes massive blood clots and sometimes leading to death. That is the same mechanism used by other vaccine manufacturers, such as Pfizer, with the same potential results in human blood vessels.
“Pfizer, Moderna, AstraZeneca, Janssen – they’re equally dangerous,” he warns. “They produce the lethal spike protein that was devised and engineered in the Chinese biosecurity lab. That's in each person who took these shots.”
At least two U.S. news outlets, The New York Times and CNN, reported AstraZeneca was pulling its COVID-19 vaccine but did not mention the UK lawsuit or the admission about blood clots.
To its credit, the story by The Hill did mention the clotting controversy – in the ninth paragraph – that said Europe witnessed reports of “rare blood clots” shortly after the shot was approved.
